Company / Total Assets
Vistagen Therapeutics, Inc. Total Assets History
FY2011-FY2023 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Total Assets
$21.1M
FY2023
5-year range
$3.7M / $108.3M
FY2019-FY2023
Trend
-71.7%
vs FY2022
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Declined from $108M to $21M over the past 2 years.
Based on SEC 10-K filings.
$21M in FY2023 with a 5-year CAGR of +13.3%.
Declined from $108M to $21M over the past 2 years.
Total Assets over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- +13.3%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of +13.3%, indicating consistent growth.
- In FY2023, total assets decreased 71.7% year-over-year.
- Peak total assets was recorded in FY2021.
- Lowest total assets in the period was in FY2012.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -7.17 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Total AssetsValue | YoY GrowthYoY |
|---|---|---|
| FY2023 | $21.1M | -71.7% |
| FY2022 | $74.6M | -31.1% |
| FY2021 | $108.3M | +860.1% |
| FY2018 | $11.3M | +203.8% |
| FY2017 | $3.7M | +321.1% |
| FY2014 | $881.5K | +158.1% |
| FY2012 | $341.6K | +0.0% |
| FY2011 | $341.6K | - |
As of FY2023 · SEC 10-K · Updated Jun 28, 2026